Literature DB >> 20666137

[A case of recurrent paraneoplastic cerebellar ataxia with antibodies to GluR epsilon 2 causally related to ganglioneuroma].

Sayaka Noguchi1, Yoshimi Kaga, Yukitoshi Takahashi, Kakuro Aoyagi, Kohsuke Nakamura, Yuko Kamiya, Takaya Nakane, Hideaki Kanemura, Kanji Sugita, Masao Aihara.   

Abstract

Acute cerebellar ataxia (ACA) in childhood following viral infection is a self-limited disease. We present a boy with recurrent episodes of paraneoplastic cerebellar ataxia associated with a ganglioneuroma. A 20-month-old boy developed the first episode of cerebellar ataxia after nonspecific respiratory tract infections. During this episode he showed a wide gait and truncal ataxia with intention tremor and horizontal nystagmus. Our initial diagnosis was ACA, and gradual improvement of ataxia was observed thereafter. At 2 years and 6 months, similar cerebellar symptoms recurred after respiratory tract infections. Speech difficulty and cognitive problems developed thereafter. We suspected paraneoplastic syndrome. Computed tomography revealed a retroperitoneal tumor, and autoantibodies against GluR epsilon 2 were detected in the cerebrospinal fluid. After the tumor resection, the cerebellar symptoms did not recur and speech difficulty and cognitive problems improved gradually. Recent neuroimaging and neuropsychological studies have revealed that cerebellar function contributes to higher brain functions including cognition and learning. We will follow up this patient's long-term cognitive function and consider special educational support and programs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20666137

Source DB:  PubMed          Journal:  No To Hattatsu        ISSN: 0029-0831


  1 in total

1.  Ataxia as Forme Fruste of Opsoclonus Myoclonus Ataxia Syndrome.

Authors:  Sumeet R Dhawan; Indar Kumar Sharawat; Renu Suthar; Deepak Bansal; Prema Menon; Bishan D Radotra; Anmol Bhatia
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.